Stroke RSS Page 3

Filtered By:
Specialty: Hematology
Condition: von Willebrand Disease

This page shows you your search results in order of relevance. This is page number 3.

Order by Relevance | Date

Total 77 results found since Jan 2013.

Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura
ConclusionIn total, 11.4% of caplacizumab‐treated patients and 43.2% of placebo‐treated patients experienced one or more major thromboembolic events, experienced an exacerbation, or died. This analysis shows the potential for caplacizumab to reduce the risk of major thromboembolic morbidities and mortality associated with aTTP.
Source: Journal of Thrombosis and Haemostasis - June 5, 2017 Category: Hematology Authors: F. Peyvandi, M. Scully, J. A. Kremer Hovinga, P. Kn öbl, S. Cataland, K. De Beuf, F. Callewaert, H. De Winter, R. K. Zeldin Tags: Brief Report Source Type: research

The role of ADAMTS13 testing in the diagnosis and management of thrombotic microangiopathies and thrombosis
ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1 motif, 13) is a metalloprotease responsible for cleavage of ultra-large von Willebrand factor (VWF) multimers. Severely deficient activity of the protease can trigger an acute episode of thrombotic thrombocytopenic purpura (TTP). Our understanding of the pathophysiology of TTP has allowed us to grasp the important role of ADAMTS13 in other thrombotic microangiopathies (TMAs) and thrombotic disorders, such as ischemic stroke and coronary artery disease. Through its action on VWF, ADAMTS13 can have prothrombotic and proinflammatory properties, not only ...
Source: Blood - August 30, 2018 Category: Hematology Authors: Masias, C., Cataland, S. R. Tags: Platelets and Thrombopoiesis, Thrombosis and Hemostasis, Review Articles, Clinical Trials and Observations Source Type: research

Reperfusion of cerebral artery thrombosis by the GPIb-VWF blockade with the Nanobody ALX-0081 reduces brain infarct size in guinea pigs
Thrombolytic therapy is the cornerstone of treatment of acute atherothrombotic ischemic stroke but is associated with brain hemorrhage; antiplatelet therapy has limited efficacy and is still associated with intracranial bleeding. Therefore, new antithrombotic approaches with a better efficacy/safety ratio are required. We have assessed the effect of ALX-0081, a Nanobody against the A1 domain of von Willebrand factor (VWF) that blocks VWF binding to GPIb, of the thrombolytic agent recombinant tissue plasminogen activator (rtPA), and of the GPIIb/IIIa antagonist tirofiban, in a middle cerebral artery (MCA) thrombosis model i...
Source: Blood - June 20, 2013 Category: Hematology Authors: Momi, S., Tantucci, M., Van Roy, M., Ulrichts, H., Ricci, G., Gresele, P. Tags: Platelets and Thrombopoiesis, Thrombosis and Hemostasis Source Type: research

The Clinical Implications of ADAMTS13 Function: The Perspectives of Haemostaseologists
This article reviews the literature in these conditions.
Source: Thrombosis Research - September 19, 2013 Category: Hematology Authors: Savita Rangarajan, Craig Kessler, Louis Aledort Tags: Mini-Reviews Source Type: research

D-dimer relates positively with increased blood pressure in black South Africans: The SABPA study
Conclusion: The black population had a more prothrombotic profile, with higher levels of coagulation markers and inhibited fibrinolysis, than the white study participants. The positive association between blood pressure and elevated D-dimer in the blacks may contribute to the high prevalence of hypertension and related increased cardiovascular and cerebrovascular risk in this group.
Source: Thrombosis Research - April 8, 2014 Category: Hematology Authors: Leandi Lammertyn, Aletta E. Schutte, Marlien Pieters, Rudolph Schutte Tags: Coagulation and Fibrinolysis Source Type: research

Management of anticoagulation and antiplatelet therapy in patients with left ventricular assist devices
Abstract Left ventricular assist devices (LVADs) have increased the survival of patients with advanced heart failure fourfold. Despite these advances, significant bleeding and thrombotic complications occur. Hemorrhage requiring surgery has been reported in up to 30 % of adults and 50 % of children after LVAD placement. LVAD thrombosis and embolic stroke lead to significant long-term morbidity. Adults are treated with antithrombotic therapy to prevent thrombotic complications, but the amount and intensity of treatment differs between institutions. The goal international normalized ratio for warfarin therapy vari...
Source: Journal of Thrombosis and Thrombolysis - December 31, 2014 Category: Hematology Source Type: research

Plasma ADAMTS13 levels and the risk of myocardial infarction: an individual patient data meta‐analysis
ConclusionLow levels of ADAMTS13 are associated with an increased risk of MI.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - June 1, 2015 Category: Hematology Authors: A. Maino, B. Siegerink, L. A. Lotta, J. T. B. Crawley, S. le Cessie, F. W. G. Leebeek, D. A. Lane, G. D. O. Lowe, F. Peyvandi, F. R. Rosendaal Tags: Original Article ‐ Cardiovascular Medicine Source Type: research

Plasma ADAMTS13 levels and the risk of myocardial infarction: an individual patient data meta-analysis.
CONCLUSION: Low levels of ADAMTS13 are associated with an increased risk of MI. This article is protected by copyright. All rights reserved. PMID: 26073931 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - June 15, 2015 Category: Hematology Authors: Maino A, Siegerink B, Lotta LA, Crawley JT, le Cessie S, Leebeek FW, Lane DA, Lowe GD, Peyvandi F, Rosendaal FR Tags: J Thromb Haemost Source Type: research

Plasma ADAMTS‐13 levels and the risk of myocardial infarction: an individual patient data meta‐analysis
ConclusionsLow ADAMTS‐13 levels are associated with an increased risk of myocardial infarction.
Source: Journal of Thrombosis and Haemostasis - July 14, 2015 Category: Hematology Authors: A. Maino, B. Siegerink, L. A. Lotta, J. T. B. Crawley, S. Cessie, F. W. G. Leebeek, D. A. Lane, G. D. O. Lowe, F. Peyvandi, F. R. Rosendaal Tags: Original Article Source Type: research

Three-year changes of prothrombotic factors in a cohort of South Africans with a high clinical suspicion of obstructive sleep apnea.
Abstract A hypercoagulable state might be one important mechanism linking obstructive sleep apnea (OSA) with incident myocardial infarction and stroke. However, previous studies on prothrombotic factors in OSA are not uniform and cross-sectional. We longitudinally studied prothrombotic factors in relation to OSA risk, adjusting for baseline levels of prothrombotic factors, demographics, metabolic parameters, aspirin use, and life style factors. The Berlin Questionnaire and/or neck circumference were used to define high OSA risk in 329 South African teachers (48.0 % male, 44.6 % black) at baseline and at three-...
Source: Thrombosis and Haemostasis - September 3, 2015 Category: Hematology Authors: von Känel R, Malan NT, Hamer M, Lambert GW, Schlaich M, Reimann M, Malan L Tags: Thromb Haemost Source Type: research

Mechanical circulatory support: balancing bleeding and clotting in high-risk patients.
Authors: Baumann Kreuziger L, Massicotte MP Abstract Mechanical circulatory support (MCS) provides a bridge to heart transplant in children and adults with life-threatening heart failure and sustains patients ineligible for transplant. Extracorporeal membrane oxygenation (ECMO) provides temporary support for patients in cardiac or pulmonary failure through external gas exchange and continuous flow of blood. Because the median time to heart transplant exceeds event-free time on ECMO, pulsatile left ventricular assist devices (LVADs) are used to support infants and children. Continuous flow LVADs are preferred in ado...
Source: Hematology ASH Education Program - December 10, 2015 Category: Hematology Tags: Hematology Am Soc Hematol Educ Program Source Type: research

Association of von Willebrand factor deficiency with prevalent cardiovascular disease and asymptomatic carotid atherosclerosis: The Atherosclerosis Risk in Communities Study
Von Willebrand factor (VWF), a large multimeric glycoprotein, plays a critical role in hemostasis. It binds to subendothelial collagen at the site of vascular injury where it facilitates platelet activation. Given the role of VWF in platelet activation, and the role of platelets in cardiovascular events, such as myocardial infarction (MI) and ischemic stroke, VWF may influence the risk of cardiovascular disease (CVD). In addition, evidence suggests that VWF may affect CVD risk by playing a role in atherogenesis by direct participation in plaque formation [1].
Source: Thrombosis Research - May 31, 2016 Category: Hematology Authors: Craig D. Seaman, Kristen M. George, Margaret Ragni, Aaron R. Folsom Source Type: research

Model systems for platelet receptor shedding.
Authors: Bender M, Stegner D, Nieswandt B Abstract Platelet adhesion and aggregation at sites of vascular injury are crucial for hemostasis; however, under pathological conditions, they can cause myocardial infarction and stroke. Platelet adhesion is mediated by binding of the glycoprotein (GP)Ib-V-IX complex to immobilized von Willebrand factor (vWF), thereby enabling the interaction of GPVI with exposed collagen and subsequent platelet activation. This process is reinforced by locally produced thrombin and platelet-derived adenosine diphosphate (ADP) and thromboxane A2 (TxA2), leading to a conformational change o...
Source: Platelets - June 24, 2016 Category: Hematology Tags: Platelets Source Type: research

How I treat patients with inherited bleeding disorders who need anticoagulant therapy
Situations that ordinarily necessitate consideration of anticoagulation, such as arterial and venous thrombotic events and prevention of stroke in atrial fibrillation, become challenging in patients with inherited bleeding disorders such as hemophilia A, hemophilia B, and von Willebrand disease. There are no evidence-based guidelines to direct therapy in these patients, and management strategies that incorporate anticoagulation must weigh a treatment that carries a risk of hemorrhage in a patient who is already at heightened risk against the potential consequences of not treating the thrombotic event. In this paper, we rev...
Source: Blood - July 13, 2016 Category: Hematology Authors: Martin, K., Key, N. S. Tags: How I Treat, Free Research Articles, Thrombosis and Hemostasis, Clinical Trials and Observations Source Type: research

Pages: 1 2 3 4 5 6